MRTX1133 MECHANISM OF ACTION - AN OVERVIEW

The identification of KRASG12C inhibitors has reignited desire in focusing on RAS proteins. This perform describes the invention on the KRASG12D-particular inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.And clinical trials of combination therapy with KRAS G12C inhibitors and immune